WO2000072810A1 - Method of treating hair loss using sulfonyl thyromimetic compounds - Google Patents
Method of treating hair loss using sulfonyl thyromimetic compounds Download PDFInfo
- Publication number
- WO2000072810A1 WO2000072810A1 PCT/US2000/005199 US0005199W WO0072810A1 WO 2000072810 A1 WO2000072810 A1 WO 2000072810A1 US 0005199 W US0005199 W US 0005199W WO 0072810 A1 WO0072810 A1 WO 0072810A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- acid
- dibromo
- hydroxy
- iodine
- Prior art date
Links
- 0 C*CIc(cc1)c(*)cc1S(c1c(C)cc(*)cc1*)(=O)=O Chemical compound C*CIc(cc1)c(*)cc1S(c1c(C)cc(*)cc1*)(=O)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Definitions
- the present invention relates to methods for treating hair loss in mammals, including arresting and / or reversing hair loss and promoting hair growth.
- Hair loss is a common problem which occurs, for example, through natural processes or is often chemically promoted through the use of certain therapeutic drugs designed to alleviate conditions such as cancer. Often such hair loss is accompanied by lack of hair regrowth which causes partial or full baldness.
- hair growth occurs by a cycle of activity which involves alternating penods of growth and rest. This cycle is often divided into three mam stages which are known as anagen, catagen, and telogen. Anagen is the growth phase of the cycle and may be characterized by penetration of the hair follicle deep into the dermis with rapid proliferation of cells which are differentiating to form hair. The next phase is catagen, which is a transitional stage marked by the cessation of cell division, and during which the hair follicle regresses through the dermis and hair growth is ceased.
- telogen is often characterized as the resting stage during which the regressed follicle contains a germ with tightly packed dermal papilla cells.
- the initiation of a new anagen phase is caused by rapid cell proliferation in the germ, expansion of the dermal papilla, and elaboration of basement membrane components.
- hair growth ceases, most of the hair follicles reside m telogen and anagen is not engaged, thus causing the onset of full or partial baldness.
- T4 thyroid hormone
- T3 thyronme
- T3 and T4 have been the subject of several patent publications relating to treatment of hair loss. See, e.g , Fischer et al., DE 1,617,477, published January 8, 1970; Mortimer, GB 2,138.286, published October 24, 1984; and Lmdenbaum, WO 96/25943, assigned to Life Medical Sciences, Inc., published August 29, 1996.
- T3 and / or T4 to treat hair loss is not practicable because these thyroid hormones are also known to induce significant cardiotoxicity See, e.g.. Walker et al.. U.S Patent No 5,284,971, assigned to Syntex, issued February 8, 1994 and Emmett et al., U.S. Patent No. 5,061,798, assigned to Smith Kline & French Laboratories, issued October 29, 1991.
- the present inventors have discovered compounds which promote hair growth without inducing cardiotoxicity.
- the present inventors have surprisingly discovered that the compounds useful in the present invention interact strongly with hair- selective thyroid hormone receptors but interact less strongly, or not at all, with heart-selective hormone receptors. These unique properties are, of course, not shared with T3 and / or T4. Accordingly, the compounds desc ⁇ bed for use m the methods and compositions herein are cardiac-spa ⁇ ng compounds useful for treating hair loss, including arresting and / or reversing hair loss and promoting hair growth.
- the present invention relates to methods for treating hair loss comprising administering a cardiac-sparmg compound which has been found by the present inventors to be particularly useful for treating hair loss in mammals, including arresting and / or reversing hair loss and promoting hair growth.
- the compounds utilized in the present method have the structure:
- R 1; R 3 , R 5 , R 3 ,, and R 41 are defined herein.
- the present invention relates to methods of using compounds and compositions which are particularly useful for treating hair loss m mammals, including arresting and / or reversing hair loss and promoting hair growth
- the present inventors have also surprisingly discovered that the preferred compounds are cardiac-spa ⁇ ng
- the preferred compounds useful in the method of the present invention are therefore, as defined herein below, cardiac-sparmg
- variable, moiety, group, or the like occurs more than one time in any variable or structure, its definition at each occurrence is independent of its definition at every other occurrence
- salt is a cationic salt formed at any acidic (e g , carboxyl) group, or an aniomc salt formed at any basic (e g , ammo) group.
- Preferred cationic salts include the alkali metal salts (such as, for example, sodium and potassium), alkaline earth metal salts (such as, for example, magnesium and calcium), and organic salts.
- Preferred aniomc salts include the hahdes (such as, for example, chloride salts) Such acceptable salts must, when administered, be approp ⁇ ate for mammalian use
- alkoxy is an oxygen radical having an alkyl substituent.
- alkoxy radicals include -O-methyl and -O-ethyl.
- alkyl is a saturated, straight or branched chain monovalent hydrocarbon radical Unless otherwise specified, alkyls have from 1 to about 4 carbon atoms (Ci - C 4 )
- Preferred alkyls include, for example, methyl, ethyl, propyl, zso-propyl, tert-butyl, w-butyl, .sec-butyl, and zso-butyl.
- biohydrolyzable amides are amides of the compounds used in the present invention which do not interfere with the activity of the compound, or that are readily converted in vivo by a mammalian subject to yield an active compound.
- biohydrolyzable esters are esters of the compounds used in the present invention which do not interfere with the activity of the compound, or that are readily converted in vivo by a mammalian subject to yield an active compound.
- biohydrolyzable imides are imides of the compounds used in the present invention which do not interfere with the activity of the compound, or that are readily converted in vivo by a mammalian subject to yield an active compound.
- Carbocychc ring As used herein, "carbocychc ring”, “carbocycle”, or the like is a hydrocarbon ⁇ ng radical
- Carbocychc rings are monocyclic or are fused, bridged, or spiro polycychc rings. Unless otherwise specified, monocyclic rings contain from 3 to about 9 atoms, preferably from about 4 to about 7 atoms, and most preferably 5 or 6 atoms
- Polycychc ⁇ ngs contain from about 7 to about 17 atoms, preferably from about 7 to about 14 atoms, and most preferably 9 or 10 atoms.
- Carbocychc ⁇ ngs (carbocycles) may be substituted or unsubstituted.
- cycloalkyl is a saturated carbocychc ⁇ ng radical having from four to six carbon atoms, such as cyclopentyl and cyclohexyl
- the cycloalkyl may be substituted with one or more alkyl groups
- haloalkyl is an alkyl moiety substituted at one or more positions with a halogen radical.
- halocycloalkyl an cycloalkyl moiety substituted at one or more positions with a halogen radical.
- halogen refers to chlorine, bromine, iodine, and fluo ⁇ ne, preferably chlo ⁇ ne, bromine, and iodine, more preferably chlorine and iodine, and most preferably iodine.
- pharmaceutically acceptable means suitable for use in a human or other mammal.
- safe and effective amount of a compound means an amount that is effective to exhibit biological activity, preferably wherein the biological activity is arresting and / or reversing hair loss or promoting hair growth, at the s ⁇ te(s) of activity m a mammalian subject, without undue adverse side effects (such as toxicity, irritation, or allergic response), commensurate with a reasonable benefit / risk ratio when used in the manner of this invention
- the present invention relates to methods of treating hair loss comprising administering a composition comp ⁇ sing a compound having the structure-
- R is -(CH 2 ) n (CHNR 7 R 8 ) m C(0)R 9 ;
- n is an integer from 1 to 3;
- (c) m is an integer from 0 to 1 ,
- R 3 and R 5 are each, independently, selected from the group consisting of chlo ⁇ ne, bromine, iodine, and -CH 3 ;
- R 7 and R 8 are each, independently, selected from the group consisting of hydrogen and Ci - C alkyl;
- R 9 is selected from the group consisting of hydroxy, d - C 4 alkoxy, and -NR 7 R 8 ;
- R 3 ⁇ is selected from the group consisting of hydrogen, chlo ⁇ ne, bromine, iodine, Ci - C 4 alkyl, C 4 - C 6 cycloalkyl, C, - C 4 haloalkyl, C 4 - C 6 halocycloalkyl, and - CH(R 10 )Ar;
- Ar is selected from the group consisting of 5-hydroxypy ⁇ d-2-yl, 6-hydroxypy ⁇ d-3- yl, 6-hydroxypy ⁇ daz ⁇ n-3-yl, 6-methoxypyndaz ⁇ n-3-yl N-oxide, and 6- hydroxypy ⁇ daz ⁇ n-3-yl N-oxide;
- Rio is selected from the group consisting of hydrogen and - C 4 alkyl;
- R 4 ⁇ is selected from the group consisting of hydroxy and C] - C alkoxy.
- the R, moiety is -(CH 2 ) n (CHNR-R 8 ) m C(0)R 9 .
- n is from 1 to 3.
- n is 1 or 2.
- m is either 0 or 1.
- R7 and R 8 are each, independently, selected from hydrogen and C] - C 4 alkyl.
- R 7 and R 8 are each hydrogen
- R 9 is selected from hydroxy, - C 4 alkyl, and -NR R 8 . As stated above, R 7 and R 8 are preferably each hydrogen
- Rj is an alkanoic or 2-ammoalkano ⁇ c acid radical derived from acetic acid, propionic acid, or 2-ammoprop ⁇ on ⁇ c acid, or the methyl or ethyl ester thereof.
- alkanoic acid radical refers to a monovalent carboxyhc acid radical formed by removal of a hydrogen from the co-carbon of an acid having from two to four carbon atoms, e.g , acetyl (-CH 2 COOH), propionyl (-CH 2 CH 2 COOH), and butyryl (-CH 2 CH 2 CH 2 COOH).
- “ammoalkanoic acid radical” refers to a monovalent alkanoic acid radical having an ammo or mono- or dialkylammo substituent on the -carbon, e g , 2-ammoprop ⁇ onyl (- CH 2 CH(NH 2 )COOH).
- R 3 and R 5 are each, independently, selected from chlorine, bromine, iodine, and -CH 3 (a methyl radical).
- R 3 and R 5 are each, independently, selected from iodine and bromine.
- R 3 and R 5 are either both bromine or both iodine.
- R 31 is selected from hydrogen, chlorine, bromine, iodine, C] - C 4 alkyl, C 4 - C 6 cycloalkyl, Q - C haloalkyl, C 4 - C 6 halocycloalkyl, and -CH(R 10 )Ar.
- Ar is selected from 5-hydroxypy ⁇ d-2-yl, 6-hydroxypy ⁇ d-3-yl, 6-hydroxypy ⁇ dazm-3-yl, 6-methoxypy ⁇ dazm-3-yl N-oxide, and 6-hydroxypy ⁇ daz ⁇ n-3-yl N-oxide.
- Ar is selected from 6-hydroxypy ⁇ d-3-yl, 6-hydroxypy ⁇ dazm-3-yl, 6-methoxypyndazm-3-yl N-oxide, and 6-hydroxypy ⁇ dazm-3-yl N-oxide
- Rio is selected from hydrogen and C] - C 4 alkyl
- R 3! is selected from iodine, .so-propyl, cyclopentyl, cyclohexyl, and - CH(R 10 )Ar
- R 4! is selected from hydroxy and C, - C 4 alkoxy, preferably hydroxy.
- a preferred alkoxy for R 41 is methoxy.
- Preferred Compounds Useful in the Present Invention Preferred compounds useful m the methods and compositions of the present invention are:
- the most preferred compounds for use m the present invention are 3,5- d ⁇ bromo-4-(3-cyclohexyl-4-hydroxyphenylsulfonyl)phenylacet ⁇ c acid and 3,5-d ⁇ bromo-4-(3- cyclohexyl-4-methoxyphenylsulfonyl)phenylacet ⁇ c acid.
- the present invention relates to methods of treating hair loss by admmiste ⁇ ng a compound having a structure as described herein.
- the compound utilized in the present invention will be cardiac-sparing Compounds (test compounds) may be tested for their ability to induce anagen and their lack of cardiotoxicity (cardiac-sparmg) using the following methods Alternatively, other methods well-known in the art may be used (but with the term "cardiac-sparmg" being defined according to the method disclosed herein below).
- the cardiotoxicity assay measures the potential of a test compound to adversely affect the cardiovascular system.
- thyroid hormone T3 damages the cardiovascular system, the heart enlarges.
- T3 thyroid hormone
- the cardiotoxicity assay herein below is used to test compounds for potentially adverse cardiac effects by measu ⁇ ng their effect on the heart-to-body weight ratio.
- the first group is a vehicle control group and the second group is a test compound group.
- the length of the assay is 30 days, with treatment of vehicle or test compound in vehicle daily for 28 of those days as described below.
- each rat Prior to initiation of the assay, each rat is allowed to acclimate to standard environmental conditions for 5 days. Each rat receives food (standard rat chow diet) and water ad libitum 5 days prior to initiation of the assay as well as to termination of the study.
- the vehicle is 91 :9 (v:v) propylene glycohethanol.
- the test compound is prepared at a concentration of 500 ⁇ g/mL in the vehicle.
- each rat is weighed on day 1 of the assay. Dosage calculations are then performed: each rat will be administered daily a dosing solution of vehicle or test compound m vehicle (depending on whether the rat is in the vehicle control group or the test compound group, respectively) at 500 ⁇ L of dosing solution per kg of rat. For rats in the test compound group, this corresponds to a dose of 250 ⁇ g of test compound per kg of rat.
- Day 2 is the first day of treatment with dosing solution for both groups. Body weights are taken for each rat on days 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, and 29 prior to dosing for that day; for each rat, the dosmg solutions are recalculated and administered accordingly upon change m body weight.
- Treatment occurs once daily m the morning on days 2 through 29, inclusive, for each rat in each group
- the dosmg solution is administered subcutaneously between the shoulders of the rat such that the injection sites are rotated in this area.
- the hearts of each rat are then excised as follows. An incision is made to expose the abdominal cavity. The ⁇ b cage is carefully cut at the sternum with small scissors, such that the heart and lungs are exposed. With small scissors and forceps, the vessels connected to the heart are cut away from the heart. These vessels include the caudal vena cava, left cranial vena cava (pulmonary trunk), right cranial vena cava, thoracic aorta, right subclavian artery, internal thoracic artery and vein, and any other small attachments. The heart is then immediately taken out intact, including the left and ⁇ ght au ⁇ cles and left and ⁇ ght vent ⁇ cles. Immediately thereafter, any excess tissue is trimmed away, the heart is lightly blotted on a paper towel until no more blood is visibly left behind on the paper towel, and the heart is weighed.
- the heart weight is divided by the body weight after euthanization for each rat to give the heart/body ratio.
- the heart/body ratios for each rat in the vehicle control group are added together and divided by 6 (i.e., the total number of rats in the group) to give RV (ratio for vehicle control group).
- RV ratio for vehicle control group
- RT ratio for test compound group
- the index C is then calculated by dividing RT by RV.
- the test compound is cardiac-sparmg.
- C is less than 1.2, more preferably less than 1.15, and most preferably less than 1.1.
- T3 and T4 are not cardiac-spa ⁇ ng.
- the Telogen Conversion Assay measures the potential of a test compound to convert mice in the resting stage of the hair growth cycle ("telogen"), to the growth stage of the hair growth cycle (“anagen").
- telogen there are three p ⁇ ncipal phases of the hair growth cycle: anagen, catagen, and telogen. It is believed that there is a longer telogen pe ⁇ od in C3H mice (Harlan Sprague Dawley, Inc., Indianapolis, IN) from approximately 40 days of age until about 75 days of age, when hair growth is synchronized. It is believed that after 75 days of age, hair growth is no longer synchronized Wherein about 40 day-old mice with dark fur (brown or black) are used in hair growth experiments, melanogenesis occurs along with hair (fur) growth wherein the topical application of hair growth mducers are evaluated.
- the Telogen Conversion Assay herein below is used to screen compounds for potential hair growth by measuring melanogenesis
- Three groups of 44 day-old C3H mice are utilized: a vehicle control group, a positive control group, and a test compound group, wherein the test compound group is administered a compound used in the method of the present invention.
- the length of the assay is at least 19 days with 15 treatment days (wherein the treatment days occur Mondays through Fridays).
- Day 1 is the first day of treatment. Most studies will end on Day 19, but a few may be carried out to Day 24 if the melanogenesis response looks positive, but occurs slowly.
- a typical study design is shown in Table 1 below. Typical dosage concentrations are set forth in Table 1 , however the skilled artisan will readily understand that such concentrations may be modified.
- the vehicle is 60% ethanol, 20% propylene glycol, and 20% dimethyl isosorbide (commercially available from Sigma Chemical Co., St. Louis, MO).
- mice are treated topically Monday through Friday on their lower back (base of tail to the lower rib).
- a pipettor and tip are used to deliver 400 ⁇ L to each mouse's back.
- the 400 ⁇ L application is applied slowly while moving hair on the mouse to allow the application to reach the skin.
- the compounds used in the methods of the present invention are prepared according to procedures which are well-known to those ordinarily skilled in the art.
- the starting mate ⁇ als used in prepa ⁇ ng the compounds are known, made by known methods, or are commercially available as a starting material.
- the compounds of the present invention may have one or more chiral centers.
- one optical isomer including diastereomers and enantiomers
- another optical isomer including diastereomers and enantiomers
- both stereoisomers or both optical isomers including diastereomers and enantiomers at once (a racemic mixture).
- the compounds of the invention may exist as racemic mixtures, mixtures of optical isomers, including diastereomers and enantiomers, may be separated using known methods, such as through the use of, for example, chiral salts and chiral chromatography.
- one optical isomer including a diastereomer and enantiomer, or a stereoisomer
- both optical isomers including diastereomers and enantiomers, or stereoisomers substantially free of the other are disclosed and claimed as well.
- the methods of the present invention are performed by administering to a mammal (preferably a human) a compound having a structure as described herein and, preferably, a pharmaceutically-acceptable or cosmetically-acceptable earner.
- the compounds herein may be used for the treatment of such conditions as treating hair loss in mammals, including arresting and / or reversing hair loss and promoting hair growth. Such conditions may manifest themselves m, for example, alopecia, including male pattern baldness and female pattern baldness.
- the compounds of the present invention are, as defined herein, cardiac- spanng.
- the compounds are formulated into pharmaceutical or cosmetic compositions for use m treatment or prophylaxis of conditions such as the foregoing.
- Standard pharmaceutical formulation techniques are used, such as those disclosed in Remington's Pharmaceutical Sciences. Mack Publishing Company, Easton, PA. (1990).
- a compound having a structure as described herein is administered per day for systemic administration. It is understood that these dosage ranges are by way of example only, and that daily administration can be adjusted depending on various factors. The specific dosage of the compound to be administered, as well as the duration of treatment, and whether the treatment is topical or systemic are interdependent.
- the dosage and treatment regimen will also depend upon such factors as the specific compound used, the treatment indication, the efficacy of the compound, the personal attributes of the subject (such as, for example, weight, age, sex, and medical condition of the subject), compliance with the treatment regimen, and the presence and severity of any side effects of the treatment.
- the subject compounds are co-admmistered with a pharmaceutically-acceptable or cosmetically-acceptable carrier (herein collectively described as “carrier”)
- carrier means one or more compatible solid or liquid filler diluents or encapsulating substances which are suitable for administration to a mammal
- compatible means that the components of the composition are capable of being commingled with a compound of the present invention, and with each other, m a manner such that there is no interaction which would substantially reduce the efficacy of the composition under ordinary use situations
- Car ⁇ ers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the animal, preferably mammal (most preferably human), being treated.
- the carrier can itself be inert or it can possess pharmaceutical and / or cosmetic benefits of its own.
- compositions of this invention may be in any of a variety of forms, suitable (for example) for oral, rectal, topical, nasal, ocular or parenteral administration. Of these, topical and / or oral administration are especially preferred with topical being most preferred.
- a variety of car ⁇ ers well-known in the art may be used These include solid or liquid fillers, diluents, hydrotropes, surface-active agents, and encapsulating substances.
- Optional pharmaceutically-active or cosmetically-active materials may be included which do not substantially interfere with the activity of the compound of the present invention.
- the amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.
- substances which can serve as earners or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its denvatives, such as sodium carboxymefhyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubncants, such as stea ⁇ c acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glyce ⁇ ne, sorbitol, manmtol, and polyethylene glycol; algmic acid; emulsifiers, such as the TWEENS; wetting agents, such sodium lauryl sulfate. coloring agents, flavoring agents, tabletmg agents, stabilizers, antioxidants; preservatives, pyr
- earners for systemic administration include sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, algmic acid, phosphate buffer solutions, emulsifiers, isotomc salme, and pyrogen- free water.
- Prefened earners for parenteral administration include propylene glycol, ethyl oleate, pynolidone, ethanol, and sesame oil
- the earner, in compositions for parenteral administration comprises at least about 90% by weight of the total composition
- oral dosage forms can be used, including such solid forms as tablets, capsules, granules and bulk powders
- These oral forms comprise a safe and effective amount, usually at least about 5%, and preferably from about 25% to about 50%, of a compound used in the present invention
- Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, or multiple-compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow- mducing agents, and melting agents.
- Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, melting agents, coloring agents and flavoring agents.
- Tablets typically comprise conventional pharmaceutically-compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, manmtol, lactose and cellulose; binders such as starch, gelatin and sucrose; dismtegrants such as starch, algmic acid and croscarmelose; lubricants such as magnesium stearate, stea ⁇ c acid and talc. Ghdants such as silicon dioxide can be used to improve flow characteristics of the powder mixture.
- Colo ⁇ ng agents such as the FD&C dyes, can be added for appearance.
- Sweeteners and flavoring agents such as aspartame, saccha ⁇ n, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets.
- Capsules typically compnse one or more solid diluents disclosed above. The selection of earner components depends on secondary considerations like taste, cost, and shelf stability, which are not c ⁇ tical for the purposes of the subject invention, and can be readily made by a person skilled in the art.
- Orally administered compositions also include liquid solutions, emulsions, suspensions, powders, granules, elixirs, tinctures, syrups, and the like.
- Typical components of earners for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water.
- typical suspending agents include methyl cellulose, sodium carboxymethyl cellulose, AVICEL RC-591, tragacanth and sodium algmate;
- typical wetting agents include lecithin and polysorbate 80;
- typical preservatives include methyl paraben and sodium benzoate.
- Peroral liquid compositions may also contain one or more components such as sweeteners, flavonng agents and colorants disclosed above.
- compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the subject compound is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action
- dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvmylacetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and shellac.
- compositions useful for attaining systemic delivery of the subject compounds include sublmgual, buccal and nasal dosage forms. Such compositions typically compnse one or more of soluble filler substances such as sucrose, sorbitol and manmtol; and binders such as acacia, microcrystallme cellulose, carboxymethyl cellulose and hydroxypropyl methyl cellulose. Ghdants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.
- the compounds of the present invention may also be topically administered.
- the earner of the topical composition preferably aids penetration of the present compounds into the skm to reach the environment of the hair follicle.
- Topical compositions of the present invention may be m any form including, for example, solutions, oils, creams, ointments, gels, lotions, shampoos, leave-on and rmse-out hair conditioners, milks, cleansers, moisturizers, sprays, sk patches, and the like.
- Topical compositions containing the active compound can be admixed with a variety of earner materials well known in the art, such as, for example, water, alcohols, aloe vera gel, allantom, glyce ⁇ ne, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 mynstyl propionate, and the like.
- emollients such as stearyl alcohol, glyceryl mono ⁇ cinoleate, glyceryl monostearate, propane- 1,2-d ⁇ ol, butane-l,3-d ⁇ ol, mink oil, cetyl alcohol, zso-propyl isostearate, stea ⁇ c acid, iso- butyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, dimethylpolysiloxane, d ⁇ - «-butyl se
- decyl oleate, and mynstyl mynstate propellants, such as propane, butane, z o-butane, dimethyl ether, carbon dioxide, and nitrous oxide; solvents, such as ethyl alcohol, methylene chloride, zso-propanol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxide, dimethyl formamide, tetrahydrofuran.
- propellants such as propane, butane, z o-butane, dimethyl ether, carbon dioxide, and nitrous oxide
- solvents such as ethyl alcohol, methylene chloride, zso-propanol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxide,
- humectants such as glycerin, sorbitol, sodium 2- pyrrol ⁇ done-5-carboxylate, soluble collagen, dibutyl phthalate, and gelatin; and powders, such as chalk, talc, fullers earth, kaolm, starch, gums, colloidal silicon dioxide, sodium polyacrylate, terra alkyl ammonium smectites, t ⁇ alkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmo ⁇ llonite clay, hydrated aluminium silicate, fumed silica, carboxyvmyl polymer, sodium carboxymethyl cellulose, and ethylene glycol monostearate.
- powders such as chalk, talc, fullers earth, kaolm, starch, gums, colloidal silicon dioxide, sodium polyacrylate, terra alkyl ammonium smectites, t ⁇ alkyl aryl ammonium smectites,
- the compounds used m the present invention may also be administered in the form of hposome delivery systems, such as small unilamellar vesicles, large umlamellar vesicles, and multilamellar vesicles.
- Liposomes can be formed from a va ⁇ ety of phosphohpids, such as cholesterol, stearylamme or phosphatidylchohnes
- a preferred formulation for topical delivery of the present compounds utilizes liposomes such as described in Dowton et al.. "Influence of Liposomal Composition on Topical Delivery of Encapsulated Cyclosponn A: I. An in vitro Study Using Hairless Mouse Skin", S TP Pharma Sciences, Vol. 3, pp.
- the compounds of the present invention may also be administered by iontophoresis. See, e.g.. internet site www.un ⁇ pr. ⁇ t a a d ⁇ pfarm erasmus/erasml4.html; Banga et al.. "Hydrogel-based Iontotherapeutic Delivery Devices for Transdermal Delivery of Peptide/Protem Drugs", Pharm Res , Vol. 10 (5), pp. 697-702 (1993), Ferry. "Theoretical Model of Iontophoresis Utilized m Transdermal Drug Delivery", Pharmaceutical Ada Helvetiae, Vol 70, pp. 279-287 (1995), Gangarosa et al..
- compositions used in the present invention may also optionally compnse an activity enhancer.
- the activity enhancer can be chosen from a wide va ⁇ ety of molecules which can function in different ways to enhance hair growth effects of a compound of the present invention.
- Particular classes of activity enhancers include other hair growth stimulants and penetration enhancers.
- Non-hmitmg examples of other hair growth stimulants which may be used in the compositions herein, including both systemic and topical compositions, include, for example, benzalkonium chlonde, benzethomum chlonde, phenol, estradiol, diphenhydramme hydrochlo ⁇ de, chlorpheniramme maleate, chlorophylhn derivatives, cholesterol, salicylic acid, cysteme, methionme, red pepper tincture, benzyl mcotmate, D,L - menthol, peppermint oil, calcium pantothenate, panthenol, castor oil, hmokitiol, prednisolone, resorcmol, monosacchandes and estenfied monosacchandes, chemical activators of protein kmase C enzymes, glycosammoglycan chain cellular uptake inhibitors, inhibitors of glycosidase activity, glycosarmnoglycanase inhibitors, est
- Non-limiting examples of penetration enhancers which may be used in the compositions herein include, for example, 2-methyl propan-2-ol, propan-2-ol, ethyl-2-hydroxypropanoate, hexan-2,5-d ⁇ ol, POE(2) ethyl ether, d ⁇ (2-hydroxypropyl) ether, pentan-2,4-d ⁇ ol, acetone, POE(2) methyl ether, 2-hydroxyprop ⁇ on ⁇ c acid, 2-hydroxyoctano ⁇ c acid, propan-1-ol, 1,4-d ⁇ oxane, tetrahydrofuran, butan-l,4-d ⁇ ol, propylene glycol dipelargonate, polyoxypropylene 15 stearyl ether, octyl alcohol, POE ester of oleyl alcohol, oleyl alcohol, lauryl alcohol, dioctyl adipate, dicapryl adipate, di-isopropyl a
- the compounds used m the present methods can be administered alone or as mixtures, and the compositions may further include additional drugs or excipients as appropriate for the indication
- kits comprising a compound and / or composition herein and information and / or instructions by words, pictures, and / or the like, that use of the kit will provide treatment for hair loss in mammals (particularly humans) including, for example, anestmg and / or reversing hair loss and / or promoting hair growth.
- the kit may comprise a compound and / or composition herein and information and / or instructions regarding methods of application of the compound and / or composition, preferably with the benefit of treating hair loss in mammals.
- composition for topical administration comprising:
- a human male subject suffering from male pattern baldness is treated by a method of this invention. Specifically, for 6 weeks, the above composition is daily administered topically to the subject.
- a composition for topical administration is made according to the method of Dowton et al., "Influence of Liposomal Composition on Topical Delivery of Encapsulated Cyclosporm A: I. An in vitro Study Using Hairless Mouse Skm", S.T.P. Pharma Sciences. Vol. 3, pp. 404 - 407 (1993), using 3,5-d ⁇ bromo-4-(3-cyclohexyl-4-methoxyphenylsulfonyl)phenylacet ⁇ c acid in lieu of cyclosporm A and using the Novasome 1 for the non-ionic liposomal formulation.
- a human male subject suffering from male pattern baldness is treated each day with the above composition. Specifically, for 6 weeks, the above composition is administered topically to the subject.
- a shampoo comprising
- a human subject suffering from male pattern baldness is treated by a method of this invention. Specifically, for 12 weeks, the above shampoo is used daily by the subject.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/980,351 US6646005B1 (en) | 1999-06-01 | 2000-03-01 | Method of treating hair loss using sulfonyl thyromimetic compounds |
AU37121/00A AU3712100A (en) | 1999-06-01 | 2000-03-01 | Method of treating hair loss using sulfonyl thyromimetic compounds |
CA002374260A CA2374260A1 (en) | 1999-06-01 | 2000-03-01 | Method of treating hair loss using sulfonyl thyromimetic compounds |
EP00915939A EP1185232A1 (en) | 1999-06-01 | 2000-03-01 | Method of treating hair loss using sulfonyl thyromimetic compounds |
MXPA01012494A MXPA01012494A (en) | 1999-06-01 | 2000-03-01 | Method of treating hair loss using sulfonyl thyromimetic compounds. |
JP2000620922A JP2003500430A (en) | 1999-06-01 | 2000-03-01 | Method of treating hair loss using a sulfonyl tyromimetic compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13702399P | 1999-06-01 | 1999-06-01 | |
US60/137,023 | 1999-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000072810A1 true WO2000072810A1 (en) | 2000-12-07 |
Family
ID=22475474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/005199 WO2000072810A1 (en) | 1999-06-01 | 2000-03-01 | Method of treating hair loss using sulfonyl thyromimetic compounds |
Country Status (8)
Country | Link |
---|---|
US (1) | US6646005B1 (en) |
EP (1) | EP1185232A1 (en) |
JP (1) | JP2003500430A (en) |
AR (1) | AR018699A1 (en) |
AU (1) | AU3712100A (en) |
CA (1) | CA2374260A1 (en) |
MX (1) | MXPA01012494A (en) |
WO (1) | WO2000072810A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
US6723744B2 (en) | 2001-09-26 | 2004-04-20 | Pfizer, Inc. | Indole carboxylic acids as thyroid receptor ligands |
US6777442B2 (en) | 2001-03-12 | 2004-08-17 | Bayer Aktiengesellschaft | Diphenyl derivatives |
KR100523503B1 (en) * | 2001-05-31 | 2005-10-26 | 화이자 프로덕츠 인크. | Method of Treating Hair Loss Using Thyromimetic Compounds |
US7169564B1 (en) | 2001-06-26 | 2007-01-30 | Anaderm Research Corporation | FKBP51/52 and CyP40-mediated mammalian hair growth |
EP2695611A1 (en) | 2012-08-06 | 2014-02-12 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12076428B2 (en) * | 2019-12-05 | 2024-09-03 | Rhodia Operations | Liquid pearlescent composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61165311A (en) * | 1985-01-14 | 1986-07-26 | Takeo Kinji | Hair tonic cosmetic |
US5284971A (en) * | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
WO1996025943A1 (en) * | 1995-02-23 | 1996-08-29 | Life Medical Sciences, Inc. | Compositions and methods for enhancing the growth of hair and restoring hair color |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB859546A (en) | 1956-05-29 | 1961-01-25 | Arthur Alfred Hellbaum | Composition for treatment of the skin |
DE1617477A1 (en) | 1967-06-22 | 1970-01-08 | Fischer Geb Beutelschiess Alwi | Organic hair growth tonic with guarantee |
US3530146A (en) | 1968-07-01 | 1970-09-22 | American Cyanamid Co | Substituted benzothiophendione compounds |
NL7003628A (en) | 1969-03-26 | 1970-09-29 | ||
US3616237A (en) | 1970-06-08 | 1971-10-26 | American Cyanamid Co | Method of preparing thiogriseofulvins |
PL119115B1 (en) | 1978-06-20 | 1981-11-30 | Univ Mikolaja Kopernika | Process for preparing novel 3',5'-disubstituted 2-/4'-hydroxybenzoyl/benzoic acids'-gidroksibeznoil/benzojjnykh kislot |
US4323691A (en) | 1979-10-09 | 1982-04-06 | Abbott Laboratories | Hydroxyaminomethyl derivatives of benzoyl di-substituted α-phenoxyalkanoyl esters |
FR2492830A1 (en) | 1980-10-29 | 1982-04-30 | Sori Soc Rech Ind | NOVEL COMPOUNDS BELONGING TO THE BENZOYL- AND A-HYDROXYBENZYL-PHENYL-OSIDES FAMILY, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION |
FR2500748A1 (en) | 1981-02-27 | 1982-09-03 | Oreal | NOVEL HAIR STAINING COMPOSITION CONTAINING MIXED PLANT POWDER, NATURAL COLORING DYE AND DILUTING AGENT |
EP0093194B1 (en) | 1982-04-30 | 1988-08-31 | Matsushita Electric Industrial Co., Ltd. | Magnetic recording medium |
PL138940B1 (en) | 1982-06-22 | 1986-11-29 | Univ Mikolaja Kopernika | Process for preparing derivatives of phenolphtalein |
JPS5941343A (en) | 1982-07-30 | 1984-03-07 | Chisso Corp | Polypropylene resin composition for container of magnetic recording material |
FR2543434B1 (en) | 1983-04-01 | 1986-03-14 | Muller International Sarl Alba | COMPOSITION AND METHOD FOR DYEING THE PILED SYSTEM. |
GB2138286B (en) | 1983-04-19 | 1986-10-08 | Dr Christopher Harry Mortimer | Pharmaceutical composition for the treatment of hair loss |
US4683241A (en) | 1984-05-21 | 1987-07-28 | G. D. Searle & Co. | Phenolic ester derivatives as elastase inhibitors |
US4771072A (en) | 1985-01-10 | 1988-09-13 | Tanabe Seiyaku Co., Ltd. | Alkoxynaphthalene derivatives |
US5061798A (en) | 1985-01-18 | 1991-10-29 | Smith Kline & French Laboratories, Ltd. | Benzyl pyridyl and pyridazinyl compounds |
US4711855A (en) | 1985-02-05 | 1987-12-08 | Ciba Corning Diagnostics Corp. | Derivatives of 3,5,3-triiodothyronine |
JPH0654381B2 (en) | 1985-12-24 | 1994-07-20 | 日本合成ゴム株式会社 | Positive resist for integrated circuit fabrication |
US4792584A (en) | 1986-05-02 | 1988-12-20 | Asahi Kasei Kogyo Kabushiki Kaisha | Adhesive compositions |
JPS6310746A (en) | 1986-07-01 | 1988-01-18 | Tanabe Seiyaku Co Ltd | Naphthalene derivative |
JPS63146845A (en) | 1986-07-01 | 1988-06-18 | Tanabe Seiyaku Co Ltd | Naphthalene derivative |
JPS63279246A (en) | 1987-05-12 | 1988-11-16 | Nippon Zeon Co Ltd | Positive photoresist composition |
AT388372B (en) | 1987-10-08 | 1989-06-12 | Tanabe Seiyaku Co | Novel naphthalene derivatives and pharmaceuticals containing them |
CH679119A5 (en) | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
IL91418A (en) | 1988-09-01 | 1997-11-20 | Rhone Poulenc Agrochimie | (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them |
PH26342A (en) | 1988-11-29 | 1992-04-29 | Univ Texas | Microbial cellulose modified during synthesis |
MY105057A (en) | 1989-01-27 | 1994-07-30 | Tanabe Seiyaku Co | A process for preparing naphthalene derivatives |
JPH02300148A (en) | 1989-05-11 | 1990-12-12 | Tanabe Seiyaku Co Ltd | Production of naphthalene derivative and synthetic intermediate thereof |
US5580722A (en) | 1989-07-18 | 1996-12-03 | Oncogene Science, Inc. | Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease |
WO1991001379A1 (en) | 1989-07-18 | 1991-02-07 | Oncogene Science, Inc. | Method of transcriptionally modulating gene expression and of discovering chemicals capable of functioning as gene expression modulators |
JP2854669B2 (en) | 1990-04-27 | 1999-02-03 | 株式会社 日立製作所 | Optical transmission body and optical transmission system and engine control system using the same |
JPH0452646A (en) | 1990-06-21 | 1992-02-20 | Mitsubishi Kasei Corp | Coating composition for photoresist |
AU1347292A (en) | 1991-01-18 | 1992-08-27 | Oncogene Science, Inc. | Methods of transcriptionally modulating gene expression of viral genes and other genes |
FR2672211B1 (en) | 1991-02-04 | 1993-05-21 | Oreal | PROCESS FOR DYEING KERATINIC FIBERS WITH A MONO- OR DIHYDROXYINDOLE AND A NON-OXIDIZING AROMATIC CARBONYL DERIVATIVE AND DYEING AGENT. |
KR950000482B1 (en) | 1991-04-30 | 1995-01-20 | 가부시키가이샤 도시바 | Resist for patterning |
JPH04368379A (en) | 1991-06-13 | 1992-12-21 | Natl Sci Council | Antithrombotic containing xanthone derivative or its ester as effective component |
DK0580550T3 (en) | 1992-07-21 | 1998-02-02 | Ciba Geigy Ag | Oxamic acid derivatives as hypercholesterolemic agents |
JPH06172340A (en) | 1992-12-10 | 1994-06-21 | Nippon Mektron Ltd | New compound of xanthone and active oxygen eliminating agent or aldose reductase inhibitor comprising the same as active ingredient |
EP0687249A1 (en) | 1993-03-03 | 1995-12-20 | Eli Lilly And Company | Balanoids |
JPH07149614A (en) | 1993-11-30 | 1995-06-13 | Shiseido Co Ltd | Hair tonic agent |
DE4405469C2 (en) | 1994-02-21 | 1996-11-07 | Ciba Geigy Ag | Process for the production of azo dyes |
JPH0892082A (en) | 1994-07-20 | 1996-04-09 | Kirin Brewery Co Ltd | Benzophenone derivative having eosinophilic leukocyte function inhibitory activity |
CZ294096B6 (en) | 1995-01-20 | 2004-10-13 | Americanácyanamidácompany | Benzophenone compounds, process of their preparation, fungicidal agents containing thereof and plant protection method |
US5773663A (en) | 1996-05-01 | 1998-06-30 | American Cyanamid Company | Fungicidal methods, compounds and compositions containing benzophenones |
JP2936557B2 (en) | 1995-03-31 | 1999-08-23 | 日本製紙株式会社 | Thermal recording medium |
JP2936556B2 (en) | 1995-03-31 | 1999-08-23 | 日本製紙株式会社 | Thermal recording medium |
US6221911B1 (en) | 1995-06-07 | 2001-04-24 | Karo Bio Ab | Uses for thyroid hormone compounds or thyroid hormone-like compounds |
FR2735367B1 (en) | 1995-06-19 | 1997-07-18 | Cird Galderma | USE OF LIGANDS SPECIFIC TO RXRS RECEPTORS |
AU6858996A (en) | 1995-08-28 | 1997-03-19 | Interlab Corporation | Pharmaceutical compositions for the treatment of infectious diseases |
CN1136197C (en) | 1996-05-30 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | Novel pyridajinone derivatives |
GB9619757D0 (en) | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
JPH10133427A (en) | 1996-11-05 | 1998-05-22 | Fuji Xerox Co Ltd | Carrier for developing electrostatic latent image, electrostatic latent image developer, and image forming method |
FR2755965B1 (en) | 1996-11-19 | 1998-12-18 | Cird Galderma | BIAROMATIC COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM AND USES |
JPH10158382A (en) | 1996-11-26 | 1998-06-16 | Asahi Chem Ind Co Ltd | Fluoropolymer |
US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
ATE293595T1 (en) | 1998-06-30 | 2005-05-15 | Univ California | THYROID HORMONE ANALOGUES AND METHOD FOR THE PRODUCTION THEREOF |
-
2000
- 2000-03-01 AU AU37121/00A patent/AU3712100A/en not_active Abandoned
- 2000-03-01 US US09/980,351 patent/US6646005B1/en not_active Expired - Fee Related
- 2000-03-01 EP EP00915939A patent/EP1185232A1/en not_active Withdrawn
- 2000-03-01 AR ARP000100914A patent/AR018699A1/en not_active Application Discontinuation
- 2000-03-01 JP JP2000620922A patent/JP2003500430A/en active Pending
- 2000-03-01 WO PCT/US2000/005199 patent/WO2000072810A1/en not_active Application Discontinuation
- 2000-03-01 MX MXPA01012494A patent/MXPA01012494A/en unknown
- 2000-03-01 CA CA002374260A patent/CA2374260A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61165311A (en) * | 1985-01-14 | 1986-07-26 | Takeo Kinji | Hair tonic cosmetic |
US5284971A (en) * | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
WO1996025943A1 (en) * | 1995-02-23 | 1996-08-29 | Life Medical Sciences, Inc. | Compositions and methods for enhancing the growth of hair and restoring hair color |
Non-Patent Citations (1)
Title |
---|
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002145222 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
US6924310B2 (en) | 2000-03-31 | 2005-08-02 | Pfizer Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
US7202275B2 (en) | 2000-03-31 | 2007-04-10 | Warner Lambert Company Llc | Malonamic acids and derivatives thereof as thyroid receptor ligands |
US6777442B2 (en) | 2001-03-12 | 2004-08-17 | Bayer Aktiengesellschaft | Diphenyl derivatives |
KR100523503B1 (en) * | 2001-05-31 | 2005-10-26 | 화이자 프로덕츠 인크. | Method of Treating Hair Loss Using Thyromimetic Compounds |
US7169564B1 (en) | 2001-06-26 | 2007-01-30 | Anaderm Research Corporation | FKBP51/52 and CyP40-mediated mammalian hair growth |
US6723744B2 (en) | 2001-09-26 | 2004-04-20 | Pfizer, Inc. | Indole carboxylic acids as thyroid receptor ligands |
EP2695611A1 (en) | 2012-08-06 | 2014-02-12 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof |
WO2014023698A1 (en) | 2012-08-06 | 2014-02-13 | Dr. August Wolff Gmbh & Co. Kg Arzneimitttel | Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2003500430A (en) | 2003-01-07 |
US6646005B1 (en) | 2003-11-11 |
AR018699A1 (en) | 2001-11-28 |
MXPA01012494A (en) | 2002-07-02 |
AU3712100A (en) | 2000-12-18 |
EP1185232A1 (en) | 2002-03-13 |
CA2374260A1 (en) | 2000-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6525094B1 (en) | Method of treating hair loss using diphenylether derivatives | |
US20080125433A1 (en) | Method of treating hair loss using thyromimetic compounds | |
AU3507600A (en) | Substituted biaryl ether compounds | |
US6646005B1 (en) | Method of treating hair loss using sulfonyl thyromimetic compounds | |
EP1185229A1 (en) | Method of treating hair loss | |
US6723717B1 (en) | Sulfur-containing thyroxane derivatives and their use as hair growth promotors | |
EP1194422A1 (en) | Biaryl compounds | |
US6680344B1 (en) | Method of treating hair loss using diphenylmethane derivatives | |
WO2000072813A1 (en) | Method of treating hair loss using diphenylmethane derivatives | |
EP1161222A1 (en) | Method of treating hair loss using non-immunosuppressive compounds | |
AU3611500A (en) | Sulfur-containing thyroxane derivatives and their use as hair growth promotors | |
WO2000018361A2 (en) | Method of treating hair loss using sulfonamides | |
WO2001010836A1 (en) | Method of treating hair loss using multivalent ketoamides and amides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN JP KR MX US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2374260 Country of ref document: CA Ref country code: CA Ref document number: 2374260 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 620922 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/012494 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 37121/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000915939 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09980351 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000915939 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000915939 Country of ref document: EP |